References
- Hellmann DB. Medical therapy for SLE. Md Med J 1991;40: 923–33.
- Robak E, Sysa-Jedrzejowska A, Robak T. [Cytokines in systemic lupus erythematosus]. Przegl Lek 1996;53:623–6.
- Robak E, Sysa-Jedrzejewska A, Dziankowska B, Torzecka D, Chojnowski K, Robak T. Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity. Arch Immunol Ther Exp (Warsz) 1998;46:375–80.
- Gilboe IM, Kvien TK, Husby G. Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years. J Ftheumatol 2001;28: 266–74.
- Lesiak A, Sysa-Jedrzejowska A, Narbutt J, Lukamowicz J, Robak E, Wozniacka A. [Proinflammatory cytokines in inactive lupus ery-thematosus patients]. Przegl Lek 2005;62:838–42.
- Waszczykowska E, Robak E, Wozniacka A, Narbutt J, Torzecka JD, Sysa-Jedrzejowska A. Estimation of SLE activity based on the serum level of chosen cytokines and superoxide radical generation. Mediators Inflamm 1999;8:93–100.
- Prokop'ev AA, Alekseeva TG, Zimina ZV, Ketlinskii SA. [The level of the tumor necrosis factor in the blood serum of patients with systemic lupus erythematosus and rheumatoid arthritis]. Ter Arkh 1993;65: 9–12.
- Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC. Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTN-Falpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus. Chin Ftheumatol 1999;18:17–22.
- Sabry AA, Elbasyouni SR, Kalil AM, bdel-Rahim M, Mohsen T, Sleem A. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus. Nephrology (Carlton) 2006;11:329–35.
- Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour ne-crosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Ftheumatol 1996;35: 1067–74.15.
- Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflamma-tory cytokine levels in systemic lupus erythematosus patients. 16. Lupus 2006;15: 268–75.
- Aten J, Roos A, Claessen N, Schilder-Tol EJ, Ten B, I, Weening JJ. Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol 2000;11: 1426–38.
- Horiuchi T, Morita C, Tsukamoto H, Mitoma H, Sawabe T, 17. Harashima S, et al. Increased expression of membrane TNF-alpha on activated peripheral CD8+ T cells in systemic lupus erythema- 18. tosus. Int J Mol Med 2006;17: 875–9.
- Pitidhammabhorn D, Kantachuvesiri S, Totemchokchyakarn K, Kitiyanant Y, Ubol S. Partial construction of apoptotic pathway in
- PBMC obtained from active SLE patients and the significance of plasma TNF-alpha on this pathway. Clin Rheumatol 2006;25: 705–14.
- Louis M, Rauch J, Armstrong M, Fitzcharles MA. Induction of autoantibodies during prolonged treatment with infliximab. J Ftheumatol 2003;30:2557–62.
- Charles PJ, Smeenk RJ, De JJ, Feldmann M, Maini RN. Assess-ment of antibodies to double-stranded DNA induced in rheuma-toid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383–90.
- Pisetsky DS. Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 2000;43:2381-2. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004;50: 3161–9.